R&D A new approach to drug design: Restoring the effectiveness o... None of us are unaware of the very real danger of ‘superbugs’ – only last month, the hospita
News Shionogi agrees $140m deal to buy antibiotic biotech Qpex While most pharma companies have exited the antibiotics area, Japanese dru
Market Access What happened to all the antibiotics? Across the world, there are reports of shortages of common antibiotics.
News Azithromycin for mild-to-moderate COVID-19 Azithromycin has been widely evaluated for its efficacy against COVID-19.
News The Post-Pandemic World of Antibiotics COVID-19 Antibiotics are cheap and common drugs used to treat bacterial infections.
News Novo Holding launches latest call for antibiotic investment ... With the focus on COVID-19 over the last year it’s easy to forget another deadly pandemic caused by antimicrobial resistance (AMR), which could lead to the most innocuous of infections beco
News ICER identifies new crop of 'unsupported' drug price rises Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
